SNMMI Clinical Trials Network Research Series for Technologists: An Introduction to Conducting Theranostic Clinical Trials.


Journal

Journal of nuclear medicine technology
ISSN: 1535-5675
Titre abrégé: J Nucl Med Technol
Pays: United States
ID NLM: 0430303

Informations de publication

Date de publication:
05 Sep 2024
Historique:
received: 01 09 2023
accepted: 14 11 2023
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 5 9 2024
Statut: epublish

Résumé

This article is intended to introduce nuclear medicine technologists (NMTs) to the nuances of radiopharmaceutical therapy clinical trials. Here, we outline the potential roles and responsibilities of the NMT in clinical trials and provide context on different aspects of radionuclide therapy. The regulatory process involving investigational therapeutic radiopharmaceuticals is seldom taught to NMT students, nor is it included in the entry-level nuclear medicine certification examinations. Often, NMTs must spend significant time preparing for therapeutic clinical trials on their own, using multiple academic sources, seeking advice from various health care professionals, and reviewing numerous trial-specific manuals to recognize the detailed requirements. The emergence of theranostics has spurred an increase in the development of therapeutic radiopharmaceuticals. Investigators with a robust nuclear medicine background are required to help develop successful therapeutic clinical trials, and well-informed NMTs are crucial to the success of such trials. This article follows a series of previous publications from the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network research series for technologists and is intended to guide the investigational radiopharmaceutical landscape.

Identifiants

pubmed: 39237336
pii: jnmt.123.266588
doi: 10.2967/jnmt.123.266588
doi:

Substances chimiques

Radiopharmaceuticals 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

184-191

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Freddy Gonzalez (F)

Department of Diagnostic Imaging, M.D. Anderson Cancer Center, Houston, Texas; jagonzalez1@mdanderson.org.

Peter J H Scott (PJH)

Department of Radiology, University of Michigan, Ann Arbor, Michigan.

Charlotte Denise Jeffers (CD)

Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; and.

S Cheenu Kappadath (SC)

Department of Imaging Physics, M.D. Anderson Cancer Center, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH